Abstract Search

ea0020p551 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

The low-dose ACTH stimulation test in the assessment of outcome of pituitary surgery for Cushing's disease

Alwani Rehmat A , De Herder Wouter W , De Jong Frank H , Van der Lely Aart-Jan , Feelders Richard A

Objective: To evaluate the results of the early postoperative low-dose (1 μg) ACTH (adrenocorticotropin) stimulation test in patients with Cushings disease (CD) in order to predict long-term outcome of transsphenoidal surgery.Methods: We reviewed the serum cortisol response to 1 μg synthetic ACTH (124) in the second week after pituitary surgery in 40 patients with Cushings disease. Median follow-up was 48.5 months (range 6&#15...

0 shares

ea0035p62 | Adrenal Medulla | ECE2014

Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGFI-R/INS-R antagonist OSI-906

Martino Maria Cristina De , Feelders Richard A. , Dogan Fadime , Koetsveld Peter M. van , Krijger Ronald R. De , Janssen Joseph A M J L , Sprij-Mooij Diana , Lamberts Steven W. J. , Herder Wouter W de , Colao Annamaria , Pivonello Rosario , Hofland Leo J

The mTOR and IGF pathways have been suggested to play a role in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, as sirolimus (S) and everolimus (E), as well as IGF1R antagonists could be a potential novel treatment for malignant PPC.The aim of this study was to evaluate the expression of the main components of the IGF/mTOR pathway in human PCC and to investigate the effects of the mTOR inhibitors S and E and of the IGF1R/insulin receptor (I...

0 shares

Endocrine Abstracts

The low-dose ACTH stimulation test in the assessment of outcome of pituitary surgery for Cushing's disease

Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGFI-R/INS-R antagonist OSI-906

BiosciAbstracts